Thomas Jens Ettrich

Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’

INTRODUCTIONnIn metastatic pancreatic ductal adenocarcinoma (mPDAC) treatment, erlotinib is known to be more effective in patients developing skin rash. Treatment with the FOLFIRINOX regimen is only performed in fit patients following defined inclusion criteria. The present study investigates the efficacy of gemcitabine plus erlotinib (gem/erlotinib) in rash-positive patients fit for FOLFIRINOX.nnnPATIENTS AND METHODSnFor this prospective phase II study, 150 patients were recruited in 20 centres. All patients received gem/erlotinib for 4 weeks (run-in phase); the subsequent treatment was determined by the development of skin rash: patients with rash grades 1-4 continued with gem/erlotinib, rash-negative patients were switched to FOLFIRINOX. Primary study end-point was to achieve a 1-year survival rate in rash-positive patients ≥40%.nnnRESULTSnNinety patients were deemed positive for skin rash by the end of the run-in phase, showing a 1-year survival rate of 40.0% (95% confidence interval [CI] 29.8-50.9). Median overall survival (OS) was 10.1 months, progression-free survival (PFS) was 3.8 months and overall response rate (ORR) was 23.3%. Patients switched to FOLFIRINOX (nxa0=xa027) had a 1-year survival rate of 48.1% (95% CI 28.7-68.1), a median OS of 10.9 months, a median PFS of 6.6 months and an ORR of 33.3%. Rash-negative patients had a lower quality of life at baseline but seemed to experience an improved control of pain during FOLFIRINOX.nnnCONCLUSIONSnFirst-line treatment with gem/erlotinib was effective in fit, rash-positive mPDAC patients achieving a 1-year survival rate comparable to previous reports for FOLFIRINOX. The study was registered at clinicaltrials.gov (NCT0172948) and Eudra-CT (2011-005471-17).

SOP – Darmpassagestörung in der Palliativmedizin

Onkologe 2017 · 23:566–572 DOI 10.1007/s00761-017-0239-1 Online publiziert: 17. Mai 2017

Erratum zu: SOP – Darmpassagestörung in der Palliativmedizin

com/syringe-driver-database-introduction.html. Zugegriffen:3.Nov.2016 14. Negro S, Reyes R, Azuara ML, Sánchez Y, Barcia E (2006) Morphine, Haloperidol and hyoscine N-butylbromide combined in s. c. infusion solutions: compatibility and stability. Int J Pharm 307(2):278–284 15. Bausewein C, Roller S, Voltz R (2015) Leitfaden Palliative Care, 5. Aufl. Urban & Fischer Elsevier, München 16. Watson M, Lucas C, Hoy A, Back I (2005) Oxford handbook of palliative care, 1. Aufl. Oxford UniversityPress,Oxford 17. Bruera E, MacEachern T, Macmillan K, Miller MJ, Hanson J (1993) Local tolerance to subcutaneous infusionsofhighconcentrationsofhydromorphone: A prospective study. J Pain Symptom Manage 8(4):201–204 18. Bausewein C (2007) Unter welchen Bedingungen istdie subkutaneGabevonFlüssigkeiten indiziert? Internist (Berl)48(4):439–441 19. Herndon C (2001) Continuous subcutaneous infusionpractices of United States hospices. J Pain SymptomManage22(6):1027–1034 20. Mitten T (2001) Subcutaneous drug infusions: a review of problems and solutions. Int J Palliat Nurs7(2):75–85 21. Eisenchals JH et al (2005) Low-dose levomepromazine in refractory emesis in advanced cancer patients: an open-label study. Palliat Med 19(1):71–75 22. Forbat L et al (2017) How and why are subcutaneous fluids administered in an advanced illness population: a systematic review. J Clin Nurs 26(9–10):1204–1216 Onkologe 2017 · 23:664–665 DOI 10.1007/s00761-017-0268-9 Online publiziert: 17. Juli 2017

SOP – Übelkeit und Erbrechen bei Palliativpatienten

Peter Thuss-Patience · Janett Markwordt · Regine Mayer-Steinacker · Thomas Ettrich · Carolin Wolf · Peter Stachura · Martin Neukirchen · Michael Thomas 1 Zentrum für Palliativmedizin, Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Comprehensive Cancer Center, Charité – Universitätsmedizin Berlin, Berlin, Deutschland 2 Klinik für Innere Medizin/Hämatologie und Internistische Onkologie/Palliativmedizin, Comprehensive Cancer Center Ulm – integratives Tumorzentrum des Universitätsklinikums und der Medizinischen Fakultät, Ulm, Deutschland 3 Klinik für Gastroenterologie, Endokrinologie, Stoffwechsel, Ernährungswissenschaften und Nephrologie, Comprehensive Cancer Center Ulm – integratives Tumorzentrum des Universitätsklinikums und der Medizinischen Fakultät, Ulm, Deutschland 4 Apotheke, Comprehensive Cancer Center (CCC) Erlangen-EMN, Universitätsklinikum Erlangen, FriedrichAlexander-Universität Erlangen-Nürnberg, Erlangen, Deutschland 5 Spezialisierte ambulante Palliativversorgung Bayreuth-Kulmbach, Bayreuth, Deutschland 6 Interdisziplinäres Zentrum für Palliativmedizin, Universitätstumorzentrum (UTZ) Düsseldorf, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland 7 Palliativmedizin der Thoraxklinik, Nationales Centrum für Tumorerkrankungen, Universitätsklinikum Heidelberg, Heidelberg, Deutschland

SOP – Darmpassagestörung in der Palliativmedizin@@@SOP—bowel dysfunction in palliative care medicine

Onkologe 2017 · 23:566–572 DOI 10.1007/s00761-017-0239-1 Online publiziert: 17. Mai 2017

SOP - Intestinal Transit Disorder in the Palliative Medicine

Onkologe 2017 · 23:566–572 DOI 10.1007/s00761-017-0239-1 Online publiziert: 17. Mai 2017